Insulin Secretion in Type 1 Diabetes

Diabetes

Volumn 53, Issue 2, 2004, Pages 426-433

  Steele, Chynna ^a   Hagopian, William A ^b   Gitelman, Stephen ^c   Masharani, Umesh ^c   Cavaghan, Melissa ^d   Rother, Kristina I ^e   Donaldson, David ^f   Harlan, David M ^e   Bluestone, Jeffrey ^c   Herold, Kevan C ^a,g  

^a Columbia University ^*  (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INDIANA UNIVERSITY   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD GLUCOSE MONITORING; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESPONSE; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TEST MEAL;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; EATING; HUMANS; INSULIN; KINETICS; POSTPRANDIAL PERIOD; RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL; REFERENCE VALUES;

EID: 10744229777     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.2.426     Document Type: Article

References (43)

1. Gorsuch AN, Spencer KM, Lister J, McNally JM, Dean BM, Bottazzo GF, Cudworth AG: Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 2:1363-1365, 1981
2. Gepts W: Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14:619-633, 1965
3. Faber OK, Binder C: B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment. Diabetologia 13:263-268, 1977
4. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Endocrinol Metab 65:30-36, 1987
5. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
6. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. Ann Intern Med 128:517-523, 1998
7. Gumpel RC: Intensive therapy preserves insulin secretion. Ann Intern Med 129:913-914, 1998
8. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS: Increased β-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 48:989-996, 1999
9. Shimada A, Charlton B, Taylor-Edwards C, Fathman CG: β-Cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice. Diabetes 45:1063-1067, 1996
10. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
11. Yki-Jarvinen H: Glucose toxicity. Endocr Rev 13:415-431, 1992
12. Unger RH, Grundy S: Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 28:119-121, 1985
13. Sabbah E, Savola K, Kulmala P, Veijola R, Vahasalo P, Karjalainen J, Akerblom HK, Knip M: Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group. J Endocrinol Metab 84:1534-1539, 1999
14. Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G, Lithner F, Littorin B, Nystrom L, Schersten B, Sundkvist G, Wibell L, Ostman J: Prognostic factors for the course of beta cell function in autoimmune diabetes. J Endocrinol Metab 85:4619-4623, 2000
15. Decochez K, Keymeulen B, Somers G, Dorchy H, De Leeuw IH, Mathieu C, Rottiers R, Winnock F, ver Elst K, Weets I, Kaufman L, Pipeleers DG: Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. Diabetes Care 23:1072-1078, 2000
16. Hramiak IM, Dupre J, Finegood DT: Determinants of clinical remission in recent-onset IDDM. Diabetes Care 16:125-132, 1993
17. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J: Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 15:66-74, 1992
18. Bonfanti R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E, Meschi F, Bosi E, Chiumello G, Bonifacio E: Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with type 1 diabetes mellitus. Diabet Med 15:844-850, 1998
19. Zamaklar M, Jotic A, Lalic N, Lalic K, Rajkovic N, Milicic T: Relation between course of disease in type 1 diabetes and islet cell antibodies. Ann N Y Acad Sci 958:251-253, 2002
20. Bonfanti R, Bognetti E, Meschi F, Brunelli A, Riva MC, Pastore MR, Calori G, Chiumello G: Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty. Acta Diabetol 35:91-95, 1998
21. Snorgaard O, Lassen LH, Binder C: Homogeneity in pattern of decline of beta-cell function in IDDM: prospective study of 204 consecutive cases followed for 7.4 yr. Diabetes Care 15:1009-1013, 1992
22. Sochett E, Daneman D: Relationship of insulin autoantibodies to presentation and early course of IDDM in children. Diabetes Care 12:517-523, 1989
23. Wallensteen M, Dahlquist G, Persson B, Landin-Olsson M, Lernmark A, Sundkvist G, Thalme B: Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 31:664-669, 1988
24. Madsbad S, Krarup T, Regeur L, Faber OK, Binder C: Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. Acta Endocrinol (Copenh) 95:359-363, 1980
25. Schiffrin A, Suissa S, Weitzner G, Poussier P, Lalla D: Factors predicting course of beta-cell function in IDDM. Diabetes Care 15:997-1001, 1992
26. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B: Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 77:98-105, 1986
27. Polonsky K, Frank B, Pugh W, Addis A, Karrison T, Meier P, Tager H, Rubenstein A: The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes 35:379-386, 1986
28. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J: Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Endocrinol Metab 51:520-528, 1980
29. Van Cauter E, Mestrez F, Sturis J, Polonsky KS: Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377, 1992
30. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698, 2002
31. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA: Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J Clin Invest 111:409-418, 2003
32. Faber OK, Binder C, Markussen J, Heding LG, Naithani VK, Kuzuya H, Blix P, Horwitz DL, Rubenstein AH: Characterization of seven C-peptide antisera. Diabetes 27 (Suppl. 1):170-177, 1978
33. Woo W, LaGasse JM, Zhou Z, Patel R, Palmer JP, Campus H, Hagopian WA: A novel high-throughput method for accurate, rapid, and economical measurement of multiple type 1 diabetes autoantibodies. J Immunol Methods 244:91-103, 2000
34. Heptulla RA, Tamborlane WV, Cavaghan M, Bronson M, Limb C, Ma YZ, Sherwin RS, Caprio S: Augmentation of alimentary insulin secretion despite similar gastric inhibitory peptide (GIP) responses in juvenile obesity. Pediatr Res 47:628-633, 2000
35. Ehrmann DA, Breda E, Cavaghan MK, Bajramovic S, Imperial J, Toffolo G, Cobelli C, Polonsky KS: Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia 45:509-517, 2002
36. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231-1239, 1988
37. Madsbad S, Krarup T, Regeur L, Faber OK, Binder C: Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics. Diabetologia 20:530-534, 1981
38. Steffes MW, Sibley S, Jackson M, Thomas W: β-Cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 26:832-836, 2003
39. Altuntas Y: A mathematical model for pattern of change in beta-cell reserve and factors affecting residual reserve within the first 2 years of type 1 diabetes. J Endocrinol Invest 25:987-992, 2002
40. Landin-Olsson M: Latent autoimmune diabetes in adults. Ann N Y Acad Sci 958:112-116, 2002
41. Jaeger C, Allendorfer J, Hatziagelaki E, Dyrberg T, Bergis KH, Federlin K, Bretzel RG: Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual beta-cell function, neuropathy or HLA-DR status. Horm Metab Res 29:510-515, 1997
42. Rorsman P, Eliasson L, Renstrom E, Gromada J, Barg S, Gopel S: The cell physiology of biphasic insulin secretion. News Physiol Sci 15:72-77, 2000
43. Grodsky GM: A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. J Clin Invest 51:2047-2059, 1972